Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Favipiravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | MC3R | P41968 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Favipiravir SCHEMBL21085196 | 0.98 | LCK (0.33) | LCKKMT2AMEN1PDPK1ADORA3 | |
| Favipiravir SCHEMBL30725561 | 0.98 | LCK (0.33) | LCKKMT2AMEN1PDPK1ADORA3 | |
| Favipiravir SCHEMBL28964779 | 0.87 | LMNA (0.32) | LMNA | |
| SCHEMBL5269681 | 0.84 | PLAU (0.33) | LCKKMT2APDPK1ADORA3TSHR | |
| SCHEMBL31259490 | 0.84 | PLAU (0.33) | LCKKMT2APDPK1ADORA3TSHR | |
| Favipiravir SCHEMBL28952948 | 0.82 | PARP1 (0.38) | — | |
| SCHEMBL28398570 | 0.82 | KDM4E (0.37) | KMT2AMEN1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL6376447 | 0.82 | KMT2A (0.32) | LCKKMT2AMEN1PDPK1ADORA3 | |
| SCHEMBL29733656 | 0.82 | KMT2A (0.32) | LCKKMT2AMEN1PDPK1ADORA3 | |
| SCHEMBL25028569 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4545 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260139035-A1 | HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2026-05-21 | — | — | US | claimed |
| US-20260130921-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem Incorporated (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-12605378-B2 | Small therapeutic molecules capable of inhibiting the catalytic activity of the main protease enzyme of SARS-CoV-2 | ISTANBUL MEDIPOL UNIVERSITESI (TR) | 2026-04-21 | — | — | US | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-2623498-A1 | SODIUM SALT OF 6-FLUORO-3-HYDROXY-2-PYRAZINE CARBOXAMIDE | Toyama Chemical Co., Ltd. (JP) | 2013-08-07 | — | — | EP | claimed |
| CN-102775358-A | Preparation method of 6-fluoro-3-hydroxy-2-pyrazinamide | SHANDONG QIDU PHARMACEUTICAL | 2012-11-14 | — | — | CN | claimed |
| CN-102655859-A | Combination therapy treatment for viral infections | GEMMUS PHARMA INC | 2012-09-05 | — | — | CN | claimed |
| EP-2488168-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | Gemmus Pharma Inc. (US) | 2012-08-22 | — | — | EP | claimed |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA, INC. (US) | 2012-07-26 | — | — | US | claimed |
| CN-102603658-A | Preparation method of 6-fluorine-3-hydroxyl-2-pyrazinamide | SHANDONG QIDU PHARMACEUTICAL | 2012-07-25 | — | — | CN | claimed |
| CN-102348458-A | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide | TOYAMA CHEMICAL CO LTD | 2012-02-08 | — | — | CN | claimed |
| EP-2407166-A1 | TABLET AND GRANULATED POWDER CONTAINING 6-FLUORO-3-HYDROXY-2-PYRAZINECARBOXAMIDE | Toyama Chemical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | claimed |
| US-20120010221-A1 | TABLET AND GRANULATED POWDER CONTAINING 6-FLUORO-3-HYDROXY-2-PYRAZINECARBOXAMIDE | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-01-12 | — | — | US | claimed |
| WO-2011047048-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA, INC. (US) | 2011-04-21 | — | — | WO | claimed |